The Affilated Hospital of Inner Mongdlia Medical University
Welcome,         Profile    Billing    Logout  
 4 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Hongbin
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Recruiting
2
120
RoW
JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Active Ankylosing Spondylitis
11/22
01/23
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Recruiting
2
120
RoW
JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Non-radiographic Axial Spondyloarthritis
04/23
06/23
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Completed
2
140
RoW
Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group
Tianjin Hemay Pharmaceutical Co., Ltd
Rheumatoid Arthritis
06/23
06/23
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Recruiting
2
261
RoW
Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005）
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Ankylosing Spondylitis
02/25
10/25
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting
2
186
RoW
Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus, SLE
08/25
05/26
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting
2
296
RoW
Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control
Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan
Connective Tissue Diseases, Thrombocytopenia
12/25
12/25
POSDOT, NCT02999932: Peripheral Oxygen Saturation (SpO2) Directed Oxygen Therapy

Terminated
N/A
1706
RoW
SpO2 directed oxygen therapy
Wuhan Union Hospital, China, Wu Jieping Medical Foundation
Critical Illness
05/22
05/22
LEFAZAREM, NCT04737343: Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis

Recruiting
N/A
114
RoW
Leflunomide, Tuoshu for commericial name, Azathioprine Tablets
Chinese SLE Treatment And Research Group, Shanghai Zhongshan Hospital, Affiliated Hospital of Jilin University, Changchun,China, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Anhui Medical University, Beijing Shijitan Hospital, Capital Medical University, The Affiliated Hospital of Inner Mongolia Medical University, The First Affiliated Hospital of Kunming Medical College, Sichuan Province People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University
ANCA Associated Vasculitis, Maintenance Therapy
11/24
12/24
NCT05376124: Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory

Recruiting
N/A
110
RoW
original therapy, rescue therapy
First Affiliated Hospital Xi'an Jiaotong University
Hepatitis B, Chronic, Virus Diseases
12/24
12/25
CAPSTONE, NCT05230017: Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

Recruiting
N/A
2000
RoW
Peking Union Medical College Hospital
Anti Phospholipid Syndrome
12/26
12/26

Download Options